Table 1 Qualitative characteristics of the included patients.
From: Impact of COVID-19 on quality of life in survivors with pulmonary sequelae
Characteristics | Total (N = 130) | Without post COVID-19 sequelae (N = 103) | Post COVID-19 sequelae (N = 27) | p |
|---|---|---|---|---|
Gender | ||||
Male | 63 (48.5) | 46 (44.7%) | 17 (63.0%) | 0.090 |
Female | 67 (51.5) | 57 (55.3%) | 10 (37.0%) | |
Hypertension | 50 (38.5) | 36 (35.0%) | 14 (51.9%) | 0.108 |
Diabetes mellitus | 13 (10.0) | 11 (10.7%) | 2 (7.4%) | 1.000 |
Pulmonary disease (chronic obstructive pulmonary disease, asthma, other) | 21 (16.2) | 16 (15.5%) | 5 (18.4%) | 0.770 |
Immunosuppression | 7 (5.4) | 5 (4.9%) | 2 (7.4%) | 0.635 |
Obesity | 38 (29.2) | 28 (27.2%) | 10 (37.0%) | 0.347 |
Smoking history | 60 (46.2) | 46 (44.7%) | 14 (51.9%) | 0.475 |
Cough | 29 (22.3) | 25 (24.3%) | 4 (14.8%) | 0.299 |
Dyspnea | 49 (37.7) | 37 (35.9%) | 12 (44.4%) | 0.394 |
Asthenia | 48 (36.9) | 40 (38.8%) | 8 (29.6%) | 0.388 |
Myalgias-arthralgias | 25 (19.2) | 20 (19.4%) | 5 (18.5%) | 0.930 |
Anosmia-dysgeusia | 31 (23.8) | 25 (24.3%) | 6 (22.2%) | 0.839 |
Memory loss | 14 (10.8) | 10 (9.7%) | 4 (14.8%) | 0.485 |
Dermatological disorders | 12 (9.2) | 9 (8.7%) | 3 (11.1%) | 0.711 |
Headache | 21 (16.2) | 17 (16.5%) | 4 (14.8%) | 1.000 |
Visual loss | 7 (5.4) | 5 (4.9%) | 2 (7.4%) | 0.633 |
Back low pain | 6 (4.6) | 4 (3.9%) | 2 (7.4%) | 0.603 |
Crackles | 12 (9.2) | 8 (7.8%) | 4 (14.8%) | 0.274 |
